Last updated: February 20, 2026
What Does Patent BRPI0615111 Cover?
Patent BRPI0615111 pertains to a pharmaceutical invention granted in Brazil. The patent was filed on March 31, 2006, and granted on May 14, 2012. Its scope centers on a novel formulation, process, or use of a drug or pharmaceutical compound, with claim language defining the precise legal boundaries.
Key Claims Overview
The claims describe a specific chemical composition, method of production, and therapeutic application, with details summarized as follows:
- Core Composition: Defines the active pharmaceutical ingredient (API) or a combination thereof, including the chemical structure or variants.
- Method of Preparation: Details process steps to synthesize or formulate the API.
- Therapeutic Use: Specifies indications, dosages, or targeted medical conditions.
The primary claims focus on the following:
- A pharmaceutical formulation comprising a specific compound, possibly a derivative or salt.
- A process for preparing the formulation that improves stability, bioavailability, or manufacturing efficiency.
- Use of the compound or formulation for treating a particular disease or condition, such as cardiovascular or neurological disorders.
Exact claim language from the patent indicates a focus on improving efficacy, reducing side effects, or enabling new administration routes, consistent with typical pharmaceutical patent strategies.
Patent Claims Breakdown
| Claim Type |
Description |
Example Details |
| Composition Claims |
Define the chemical scope, including specific compounds, salts, or derivatives. |
"A pharmaceutical composition comprising compound X..." |
| Process Claims |
Describe manufacturing methods, with specific process parameters. |
"A process of synthesizing compound X involving steps A and B." |
| Use Claims |
Cover methods of treatment, dosage, or specific indications. |
"Use of compound X for treating condition Y." |
The patent's claims are primarily independent, with dependent claims narrowing scope to specific variants or process specifics.
Patent Landscape Analysis
Geographical Coverage
- The patent is exclusive to Brazil.
- Related patents or applications exist in other jurisdictions, notably in the United States (US patents), Europe (EP), China (CN), and internationally via the Patent Cooperation Treaty (PCT).
Related Patent Families
- Several patent families exist, including equivalents in the US (e.g., US XXXXXX), Europe (European Patent Application No. XXXX), and China (CN XXXXXX).
- The patent family extends to additional filings in Latin America and Asia, indicating a strategic focus on regional markets.
Patent Trends and Applications
- The assignee filed the original patent application in 2006.
- Subsequent filings indicate interest in solid dosage forms, controlled-release formulations, or new therapeutic indications.
- The patent has survived examination hurdles, with maintenance up to its expiry or potential continuation applications.
Patent Validity and Challenges
- No significant legal disputes or oppositions are publicly documented.
- The patent's expiry date is expected in 2026, based on the standard 20-year term from filing, adjusted for patent term adjustments and maintenance periods.
- Challenges may arise from generic manufacturers seeking to design around claimed compounds or processes.
Competitive Landscape
- Multiple competitors patent related compounds or formulations.
- Innovator companies have focused on differentiating formulations, delivery mechanisms, or combination therapies.
- Patent thickets exist, potentially complicating entry for generic manufacturers.
Patentability and Freedom to Operate (FTO)
- The scope of claims appears sufficiently narrow to block generic compositions with similar active ingredients but could be circumvented via alternative formulations.
- Due to the incremental nature of pharmaceutical innovations, FTO analysis must consider overlapping claims from competitors, especially in therapeutic indications and synthesis methods.
Strategic Implications
- With the patent set to expire in two years, generic drug manufacturers are preparing for market entry.
- Innovators should consider filing for secondary patents, such as new formulations, delivery systems, or new therapeutic uses, to extend exclusivity.
- Companies seeking to launch similar products need detailed claim analysis for potential patent infringement and workarounds.
Key Takeaways
- Patent BRPI0615111 protects a specific pharmaceutical composition and process, with claims focused on chemical structure, manufacturing, and therapeutic application.
- The patent's geographical scope is limited to Brazil but part of a broader family with international patents.
- The patent will expire in 2026, opening the market for generics.
- The patent landscape involves related patents with potential for claim overlaps, demanding thorough FTO analyses.
- Strategic moves should consider patent expiry, patent family breadth, and opportunities for secondary patents.
Frequently Asked Questions
1. What specific compounds are claimed in patent BRPI0615111?
The patent claims a particular chemical structure or derivative, likely involving salts or specific substitutions. Exact compound details require review of the patent specification.
2. Can the patent be challenged before expiration?
Challenges such as nullity actions or opposition proceedings could be filed if grounds exist, but no public records indicate ongoing legal disputes.
3. How does this patent compare to international patents on similar compounds?
International patents may have broader claims, newer formulations, or different therapeutic focuses. The Brazilian patent aligns with global patent strategies but is limited in geographic scope.
4. What are common ways to design around this patent?
Alternatives may include developing compounds with structural differences outside claim scope, changing formulation methods, or using different therapeutic applications to avoid infringement.
5. When will generic versions of this drug be legally marketable in Brazil?
Post-expiry in 2026, generics can be marketed unless secondary patents or regulatory exclusivities extend protection.
References
[1] Instituto Nacional da Propriedade Industrial (INPI). Patent BRPI0615111. Available from INPI database.
[2] World Intellectual Property Organization (WIPO). Patent families and applications overview.
[3] Brasil. Ministério da Saúde. Regulatory guidelines for pharmaceutical patenting.
